Quest Diagnostics (NYSE:DGX) Shares Unloaded Rep. Julie Johnson

Representative Julie Johnson (D-Texas) recently sold shares of Quest Diagnostics Incorporated (NYSE:DGX). In a filing disclosed on December 11th, the Representative disclosed that they had sold between $1,001 and $15,000 in Quest Diagnostics stock on November 3rd. The trade occurred in the Representative’s “MERRILL LYNCH LONG TERM GROWTH” account.

Representative Julie Johnson also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Charles Schwab (NYSE:SCHW) on 11/13/2025.
• Sold $1,001 – $15,000 in shares of UnitedHealth Group (NYSE:UNH) on 11/13/2025.
• Sold $1,001 – $15,000 in shares of Cigna Group (NYSE:CI) on 11/13/2025.
• Sold $1,001 – $15,000 in shares of Xcel Energy (NASDAQ:XEL) on 11/13/2025.
• Sold $1,001 – $15,000 in shares of Capital One Financial (NYSE:COF) on 11/13/2025.
• Sold $1,001 – $15,000 in shares of Walmart (NASDAQ:WMT) on 11/13/2025.
• Sold $1,001 – $15,000 in shares of Seagate Technology (NASDAQ:STX) on 11/13/2025.
• Sold $1,001 – $15,000 in shares of Wells Fargo & Company (NYSE:WFC) on 11/13/2025.
• Sold $1,001 – $15,000 in shares of Texas Instruments (NASDAQ:TXN) on 11/13/2025.
• Sold $1,001 – $15,000 in shares of The Goldman Sachs Group (NYSE:GS) on 11/13/2025.

Quest Diagnostics Price Performance

Shares of NYSE:DGX opened at $182.58 on Monday. The firm’s 50 day moving average is $183.61 and its two-hundred day moving average is $179.71. The firm has a market capitalization of $20.31 billion, a P/E ratio of 21.43, a PEG ratio of 2.41 and a beta of 0.62. The company has a current ratio of 1.13, a quick ratio of 1.04 and a debt-to-equity ratio of 0.71. Quest Diagnostics Incorporated has a 52 week low of $148.70 and a 52 week high of $197.55.

Quest Diagnostics (NYSE:DGX) last issued its quarterly earnings data on Tuesday, October 21st. The medical research company reported $2.60 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.51 by $0.09. Quest Diagnostics had a return on equity of 15.47% and a net margin of 8.91%.The business had revenue of $2.82 billion during the quarter, compared to the consensus estimate of $2.73 billion. During the same period in the previous year, the firm posted $2.30 earnings per share. The business’s revenue was up 13.2% on a year-over-year basis. Quest Diagnostics has set its FY 2025 guidance at 9.760-9.840 EPS. Analysts anticipate that Quest Diagnostics Incorporated will post 9.7 earnings per share for the current year.

Quest Diagnostics Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, January 28th. Shareholders of record on Tuesday, January 13th will be given a $0.80 dividend. The ex-dividend date is Tuesday, January 13th. This represents a $3.20 annualized dividend and a yield of 1.8%. Quest Diagnostics’s dividend payout ratio is 37.56%.

Hedge Funds Weigh In On Quest Diagnostics

Several large investors have recently made changes to their positions in the business. Boston Partners bought a new stake in Quest Diagnostics during the first quarter worth approximately $388,724,000. Norges Bank acquired a new stake in shares of Quest Diagnostics during the 2nd quarter valued at $238,122,000. EdgePoint Investment Group Inc. lifted its position in shares of Quest Diagnostics by 66,757.0% during the 3rd quarter. EdgePoint Investment Group Inc. now owns 849,752 shares of the medical research company’s stock valued at $161,946,000 after acquiring an additional 848,481 shares during the last quarter. M&G PLC grew its holdings in shares of Quest Diagnostics by 256.5% in the 2nd quarter. M&G PLC now owns 1,072,721 shares of the medical research company’s stock worth $193,090,000 after acquiring an additional 771,824 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD raised its position in shares of Quest Diagnostics by 9.0% during the first quarter. Price T Rowe Associates Inc. MD now owns 5,984,238 shares of the medical research company’s stock worth $1,012,534,000 after purchasing an additional 493,960 shares during the period. Institutional investors own 88.06% of the company’s stock.

Insider Buying and Selling at Quest Diagnostics

In related news, Director Vicky B. Gregg sold 1,250 shares of the stock in a transaction on Tuesday, November 25th. The stock was sold at an average price of $191.76, for a total value of $239,700.00. Following the completion of the transaction, the director owned 17,037 shares in the company, valued at $3,267,015.12. This trade represents a 6.84% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, SVP Michael E. Prevoznik sold 227 shares of the business’s stock in a transaction dated Friday, September 26th. The stock was sold at an average price of $188.13, for a total value of $42,705.51. Following the sale, the senior vice president owned 38,117 shares in the company, valued at approximately $7,170,951.21. The trade was a 0.59% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 94,461 shares of company stock valued at $17,957,361 over the last 90 days. 8.16% of the stock is owned by insiders.

Analyst Ratings Changes

Several research firms have recently issued reports on DGX. Baird R W cut Quest Diagnostics from a “strong-buy” rating to a “hold” rating in a research note on Monday, August 25th. Morgan Stanley set a $207.00 target price on shares of Quest Diagnostics and gave the company an “overweight” rating in a research report on Wednesday, October 22nd. Evercore ISI raised their target price on shares of Quest Diagnostics from $185.00 to $190.00 and gave the company an “in-line” rating in a research note on Wednesday, October 8th. Mizuho upped their price target on shares of Quest Diagnostics from $190.00 to $210.00 and gave the stock an “outperform” rating in a research note on Friday, October 17th. Finally, Barclays increased their price objective on shares of Quest Diagnostics from $190.00 to $195.00 and gave the company an “equal weight” rating in a report on Wednesday, October 22nd. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and ten have assigned a Hold rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $197.27.

About Representative Johnson

Julie Johnson (Democratic Party) is a member of the U.S. House, representing Texas’ 32nd Congressional District. She assumed office on January 3, 2025. Her current term ends on January 3, 2027.

Johnson (Democratic Party) ran for election to the U.S. House to represent Texas’ 32nd Congressional District. She won in the general election on November 5, 2024.

Julie Johnson earned a B.A. in history and government from the University of Texas at Austin in 1987 and a J.D. from the University of Houston Law Center in 1991. Johnson’s career experience includes working as an attorney.

Quest Diagnostics Company Profile

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.